COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022
(2022) In Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 27(18).- Abstract
We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/be0b6d9a-7931-42de-9435-5f0889f9cd8b
- author
- Björk, Jonas LU ; Bonander, Carl ; Moghaddassi, Mahnaz LU ; Rasmussen, Magnus LU ; Malmqvist, Ulf LU ; Inghammar, Malin LU and Kahn, Fredrik LU
- organization
-
- Division of Occupational and Environmental Medicine, Lund University
- EpiHealth: Epidemiology for Health
- eSSENCE: The e-Science Collaboration
- Social Medicine and Global Health (research group)
- Infection Medicine (BMC)
- Translational infection medicine (research group)
- Neutrophils – new mechanisms and new biomarkers (research group)
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- epidemiological surveillance, SARS-CoV-2 vaccine effectiveness, variant of concern
- in
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
- volume
- 27
- issue
- 18
- publisher
- European Centre for Disease Prevention and Control (ECDC)
- external identifiers
-
- scopus:85129356434
- pmid:35514304
- ISSN
- 1560-7917
- DOI
- 10.2807/1560-7917.ES.2022.27.18.2200322
- project
- Improved preparedness for future pandemics and other health crises through large-scale disease surveillance
- language
- English
- LU publication?
- yes
- id
- be0b6d9a-7931-42de-9435-5f0889f9cd8b
- date added to LUP
- 2022-07-06 15:24:31
- date last changed
- 2024-09-19 19:03:29
@article{be0b6d9a-7931-42de-9435-5f0889f9cd8b, abstract = {{<p>We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.</p>}}, author = {{Björk, Jonas and Bonander, Carl and Moghaddassi, Mahnaz and Rasmussen, Magnus and Malmqvist, Ulf and Inghammar, Malin and Kahn, Fredrik}}, issn = {{1560-7917}}, keywords = {{epidemiological surveillance; SARS-CoV-2 vaccine effectiveness; variant of concern}}, language = {{eng}}, number = {{18}}, publisher = {{European Centre for Disease Prevention and Control (ECDC)}}, series = {{Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin}}, title = {{COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022}}, url = {{http://dx.doi.org/10.2807/1560-7917.ES.2022.27.18.2200322}}, doi = {{10.2807/1560-7917.ES.2022.27.18.2200322}}, volume = {{27}}, year = {{2022}}, }